MerckAnnouncesFirstPatientDosedinPhase3StudyforInvestigationalAntibody-DrugConjugateinColorectalCancer
===2026/5/22 9:21:42===
ates and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
1
World Health Organization Colorectal cancer: Key facts. Accessed 8 May 2026. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer.
2
Kopetz S BV, et al. M9140, a novel anti-CEACAM5 antibody–drug conjugate with a potent topoisomerase 1 inhibitor payload (exatecan): preclinical data and results from a phase 1 dose-escalation study in patients with metastatic colorectal cancer (PROCEADE-CRC-01). Natu
=*=*=*=*=*=
当前为第8/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页